Heart disease (Hagerstown, Md.)最新文献_第4页

Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. 利钠肽:在心力衰竭中的生化、生理和治疗作用。

Heart disease (Hagerstown, Md.) Pub Date : 2003-05-01 DOI: 10.1097/01.HDX.0000074517.30102.64

George Stoupakis, Marc Klapholz

{"title":"Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure.","authors":"George Stoupakis, Marc Klapholz","doi":"10.1097/01.HDX.0000074517.30102.64","DOIUrl":"https://doi.org/10.1097/01.HDX.0000074517.30102.64","url":null,"abstract":"Cardiac natriuretic peptides are a family of structurally related peptides that are important in sodium and volume homeostasis. They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction. In contrast with vasoconstrictive hormones, such as norepinephrine, angiotensin II, and arginine vasopressin, which worsen the physiological milieu in patients with left ventricular dysfunction and heart failure, the natriuretic peptides ameliorate these effects by promoting natriuresis, diuresis, peripheral vasodilation, and by inhibiting the renin-angiotensin system. The serum levels of the natriuretic peptides correlate with the severity of heart failure and appear to have prognostic value. The present article reviews the biochemistry, molecular biology, and physiology of natriuretic peptides and their pathophysiological link to heart failure. The therapeutic uses of natriuretic peptides are also reviewed. This includes the use of intravenous nesiritide, a synthetic human brain natriuretic peptide, and the recently developed vasopeptidase inhibitors which are designed to inhibit the degradation of natriuretic peptides.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"5 3","pages":"215-23"},"PeriodicalIF":0.0,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.HDX.0000074517.30102.64","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22416482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 83

Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation. 心得安与缓释心得安或心得安CR (innopran XL)单次和多次给药后的药代动力学。

Heart disease (Hagerstown, Md.) Pub Date : 2003-05-01 DOI: 10.1097/01.HDX.0000074436.09658.3b

Domenic Sica, William H Frishman, Neil Manowitz

{"title":"Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.","authors":"Domenic Sica, William H Frishman, Neil Manowitz","doi":"10.1097/01.HDX.0000074436.09658.3b","DOIUrl":"https://doi.org/10.1097/01.HDX.0000074436.09658.3b","url":null,"abstract":"Blood pressure rises rapidly upon waking and may be responsible, in part, for the increased incidence of myocardial infarction and stroke during the morning hours. Current formulations and dosing of antihypertensive drugs do not provide maximum coverage during this vulnerable period. This study was performed to demonstrate that propranolol CR (Innopran XL), a novel chronotherapeutic formulation of propranolol designed for nighttime dosing, has appropriate pharmacokinetics to provide maximum cardioprotective effect in the morning. Pharmacokinetics of propranolol CR and sustained-release propranolol after single and multiple doses were determined in normal male volunteers in this open-label, 2-period crossover study. The drugs were dosed in the evening and serial blood samples were taken for determination of propranolol concentration the next 24 to 72 hours. After a single 160-mg dose of propranolol CR administered at 10 pm, absorption was delayed by about 4 hours, after which plasma concentration rose steadily, reaching a peak at about 10:00 am. In contrast, after dosing with sustained release propranolol, plasma levels of propranolol began to rise almost immediately, reaching a plateau between 4:00 am and 10:00 am. During multiple dosing, steady-state trough plasma concentrations were achieved after 2 days with either drug. After the final dose, the plasma profiles of both drugs were similar to those observed in the single-dose study. Bioavailability was similar for both formulations of propranolol. Propranolol CR exhibited appropriate pharmacokinetics for a chronotherapeutic approach to the treatment of hypertension.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"5 3","pages":"176-81"},"PeriodicalIF":0.0,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.HDX.0000074436.09658.3b","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22416479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 46

Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy. 性别、种族和基因与心血管疾病有关。第二部分:对药物治疗的启示。

Heart disease (Hagerstown, Md.) Pub Date : 2003-05-01 DOI: 10.1097/01.HDX.0000074437.07268.00

Benjamin M Schaefer, Vincent Caracciolo, William H Frishman, Pamela Charney

引用次数: 13

Aldosterone receptor blockade: a therapy resurrected. 醛固酮受体阻断:一种复活的疗法。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061693.73631.e4

Domenic A Sica

引用次数: 6

Clopidogrel in the management of ischemic heart disease. 氯吡格雷在缺血性心脏病治疗中的作用。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061697.22030.e5

Erdal Cavusoglu, Judy Cheng, Rajat Bhatt, Prabhakara B Kunamneni, Jonathan D Marmur, Calvin Eng

{"title":"Clopidogrel in the management of ischemic heart disease.","authors":"Erdal Cavusoglu, Judy Cheng, Rajat Bhatt, Prabhakara B Kunamneni, Jonathan D Marmur, Calvin Eng","doi":"10.1097/01.hdx.0000061697.22030.e5","DOIUrl":"https://doi.org/10.1097/01.hdx.0000061697.22030.e5","url":null,"abstract":"Ischemic heart disease (IHD) represents a pathophysiologic continuum consisting of stable angina, unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. Patients who develop a change in their usual stable pattern of ischemia are classified as having an acute coronary syndrome, which includes patients with unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. Such progression from a stable to an unstable state is believed to result from disruption of an atherosclerotic plaque with subsequent platelet aggregation and thrombus formation. This, in turn, leads to the clinical manifestations of unstable angina, MI or death. Because platelets play a central role in the thrombotic complications of atherosclerosis, antiplatelet agents have been the cornerstone of the therapy for IHD. Aspirin has been the traditional antiplatelet agent, and remains the mainstay of treatment for all forms of IHD. However, aspirin is a weak antiplatelet agent and is often poorly tolerated by many patients. Clopidogrel is a new antiplatelet agent of the thienopyridine class. Clopidogrel, when used alone, and especially in combination with aspirin, has been shown to improve outcomes in patients with IHD across a variety of syndromes. However, combination therapy with aspirin and clopidogrel has been associated with an increased risk of bleeding. Therefore, despite improved outcomes, further studies are required to determine the optimal duration and dosage regimen of such combination therapy to maximize its risk-benefit ratio.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"5 2","pages":"144-52"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hdx.0000061697.22030.e5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22356582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Manual of Cardiovascular Diagnosis and Therapy, 5th edition 心血管诊疗手册，第5版

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/00132580-200303000-00011

R. Kay

引用次数: 0

Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. 选择性血清素再摄取抑制剂和其他新型抗抑郁药对心血管的影响。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061695.97215.64

Imran S Khawaja, Robert E Feinstein

引用次数: 31

Breath markers of oxidative stress in patients with unstable angina. 不稳定心绞痛患者氧化应激的呼吸标志物。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061701.99611.e8

Michael Phillips, Renee N Cataneo, Joel Greenberg, Richard Grodman, Manuel Salazar

{"title":"Breath markers of oxidative stress in patients with unstable angina.","authors":"Michael Phillips, Renee N Cataneo, Joel Greenberg, Richard Grodman, Manuel Salazar","doi":"10.1097/01.hdx.0000061701.99611.e8","DOIUrl":"https://doi.org/10.1097/01.hdx.0000061701.99611.e8","url":null,"abstract":"Cardiac chest pain is accompanied by oxidative stress, which generates alkanes and other volatile organic compounds (VOCs). These VOCs are excreted in the breath and could potentially provide a rational diagnostic marker of disease. The breath methylated alkane contour (BMAC), a 3-dimensional surface plot of C4-C20 alkanes and monomethylated alkanes, provides a comprehensive set of markers of oxidative stress. In this pilot study, we compared BMACs in patients with unstable angina pectoris and in healthy volunteers. Breath VOCs were analyzed in 30 patients with unstable angina confirmed by coronary angiography and in 38 age-matched healthy volunteers with no known history of heart disease (mean age +/- SD, 62.7 +/- 12.3 years and 62.5 +/- 10.0, not significant). BMACs in both groups were compared to identify the combination of VOCs that provided the best discrimination between the 2 groups. Forward stepwise entry discriminant analysis selected 8 VOCs to construct a predictive model that correctly classified unstable angina patients with sensitivity of 90% (27 of 30) and specificity of 73.7% (28 of 38). On cross-validation, sensitivity was 83.3% (25 of 30) and specificity was 71.1% (27 of 38). We conclude that the breath test distinguished between patients with unstable angina and healthy control subjects.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"5 2","pages":"95-9"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hdx.0000061701.99611.e8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22357184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 61

Nicotine gum-induced atrial fibrillation. 尼古丁口香糖诱发心房颤动。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061700.11321.1a

Nagaraju L Choragudi, Wilbert S Aronow, Albert J DeLuca

引用次数: 20

Bosentan. 波生坦。

Heart disease (Hagerstown, Md.) Pub Date : 2003-03-01 DOI: 10.1097/01.hdx.0000061696.83820.51

Judy W M Cheng

{"title":"Bosentan.","authors":"Judy W M Cheng","doi":"10.1097/01.hdx.0000061696.83820.51","DOIUrl":"https://doi.org/10.1097/01.hdx.0000061696.83820.51","url":null,"abstract":"Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance. ET also plays an important role in the pathophysiology of different vascular diseases. Therefore, bosentan also may have the potential to alter the outcome of many other diseases, such as heart failure, hypertension, ischemic heart disease, and renal disease, as well as cerebrovascular disorders. Because of the rarity and the poor prognosis of patients with PAH, as well as the requirement of close monitoring of bosentan (due to its potential of causing liver dysfunction and its teratogenic effects), bosentan is currently available only through a special access program and is distributed by certain selected pharmacies. Patients who are receiving bosentan should be taught to recognize early signs and symptoms of liver dysfunction and possible pregnancy. In addition, bosentan is not only a substrate but also an inducer of CYP3A4 and CYP2C9. Therefore, it is anticipated that numerous drug interactions may occur. Patients should be advised to consult their physicians or pharmacists should they need to consume other prescription or nonprescription medications.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"5 2","pages":"161-9"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hdx.0000061696.83820.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22356541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0